Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783828 | 0.85 | TDP1 (0.48) | TSHRCYP3A4TDP1MEN1KMT2A | |
| SCHEMBL6800906 | 0.84 | TDP1 (0.38) | TSHRCYP3A4TDP1MEN1KMT2A | |
| SCHEMBL1028967 | 0.82 | TDP1 (0.50) | TSHRCYP3A4TDP1MEN1KMT2A | |
| SCHEMBL58127 | 0.82 | HSD17B10 (0.54) | TSHRCYP3A4TDP1ALDH1A1MAPT | |
| SCHEMBL1028675 | 0.80 | GPR35 (0.47) | TSHRCYP3A4TDP1MEN1KMT2A | |
| SCHEMBL247495 | 0.80 | PARP1 (0.41) | TSHRCYP3A4TDP1MEN1KMT2A | |
| SCHEMBL710076 | 0.80 | ALDH1A1 (0.47) | TSHRCYP3A4TDP1MEN1KMT2A | |
| SCHEMBL19859 | 0.80 | VCAM1 (0.46) | TSHRCYP3A4TDP1ALDH1A1GPR35 | |
| SCHEMBL5675005 | 0.80 | TDP1 (0.35) | TSHRCYP3A4TDP1MEN1KMT2A | |
| SCHEMBL232839 | 0.80 | TDP1 (0.39) | TSHRCYP3A4TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11193155-B2 | Designer α 6-fucosidase mutants enable direct core fucosylation of intact N-glycopeptides and N-glycoproteins | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2021-12-07 | — | — | US | claimed |
| US-20190185898-A1 | DESIGNER alpha 6-FUCOSIDASE MUTANTS ENABLE DIRECT CORE FUCOSYLATION OF INTACT N-GLYCOPEPTIDES AND N-GLYCOPROTEINS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2019-06-20 | — | — | US | claimed |
| EP-3497229-A1 | DESIGNER ALPHA 1,6-FUCOSIDASE MUTANTS ENABLE DIRECT CORE FUCOSYLATION OF INTACT N-GLYCOPEPTIDES AND N-GLYCOPROTEINS | University of Maryland, College Park (US) | 2019-06-19 | — | — | EP | claimed |
| CN-109715819-A | Designer's α 1,6- fucoside enzyme mutant realizes the direct core fucosylation of complete N- glycopeptide and N- glycoprotein | 马里兰大学帕克分校 | 2019-05-03 | — | — | CN | claimed |
| EP-2814831-B1 | NEW QUATERNARY AMMONIUM SALTS, METHOD FOR PREPARATION AND APPLICATIONS THEREOF | UNIV MEDYCZNY IM KAROLA MARCINKOWSKIEGO (PL) | 2018-08-01 | — | — | EP | claimed |
| WO-2018031734-A1 | DESIGNER α1,6-FUCOSIDASE MUTANTS ENABLE DIRECT CORE FUCOSYLATION OF INTACT N-GLYCOPEPTIDES AND N-GLYCOPROTEINS | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2018-02-15 | — | — | WO | claimed |
| US-9169267-B2 | Quaternary ammonium salts, method for preparation and applications thereof | UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO (PL) | 2015-10-27 | — | — | US | claimed |
| US-20150080583-A1 | QUATERNARY AMMONIUM SALTS, METHOD FOR PREPARATION AND APPLICATIONS THEREOF | UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO (PL) | 2015-03-19 | — | — | US | claimed |
| EP-2814831-A1 | NEW QUATERNARY AMMONIUM SALTS, METHOD FOR PREPARATION AND APPLICATIONS THEREOF | Uniwersytet Medyczny Im. Karola Marcinkowskiego (PL) | 2014-12-24 | — | — | EP | claimed |
| CN-102388060-B | Actagardine derivatives | NOVACTA BIOSYSTEMS LTD | 2014-09-10 | — | — | CN | claimed |
| WO-1998003475-A1 | PESTICIDAL COMPOSITIONS | NOVARTIS AG (CH) | 1998-01-29 | — | — | WO | claimed |
| EP-0421774-B1 | Process for production of optically active 2-(tetrahydropyran-2-yloxy)-1-propanol | TAKASAGO PERFUMERY CO LTD (JP) | 1994-06-15 | — | — | EP | claimed |
| US-5128489-A | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 2-(TETRAHYDROPYRAN-2-YLOXY)-1-PROPANOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1992-07-07 | — | — | US | claimed |
| EP-0421774-A2 | Process for production of optically active 2-(tetrahydropyran-2-yloxy)-1-propanol | Takasago International Corporation (JP) | 1991-04-10 | — | — | EP | claimed |
| US-4818692-A | COLORIMETRIC ANALYSIS WITH OLIGOSACCHARIDE | BOEHRINGER MANNHEIM GMBH (DE) | 1989-04-04 | — | — | US | claimed |
| US-4709020-A | Heptaose compounds and preparation thereof | BOEHRINGER MANNHEIM GMBH (DE) | 1987-11-24 | — | — | US | claimed |
| US-4521430-A | VASODILATOR, ANTIISCHEMIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1985-06-04 | — | — | US | claimed |
| EP-0128462-A1 | Novel benzothiazepine derivatives, processes for preparing the same and pharmaceutical compositions | Tanabe Seiyaku Co., Ltd. (JP) | 1984-12-19 | — | — | EP | claimed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | claimed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080583-A1 | QUATERNARY AMMONIUM SALTS, METHOD FOR PREPARATION AND APPLICATIONS THEREOF | UFM1, UFL1, UBAP2L | TSHR 3244/4885CYP3A4 1549/4885TDP1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.